NCT05584241Completed
Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure
Behavioral Change Following Culturally Informed Biomarker Disclosure in Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 14 Aug 2026
Brief summary (registry, in English)
The proposed project will assess long-term changes to health/lifestyle, advanced planning, and research engagement that Black and White patients with Amnestic Mild Cognitive Impairment (aMCI) make following disclosure of positron emission tomography-based amyloid and tau burden and associated risk of conversion to Dementia-Alzheimer's Type. Healthcare access will be explored as potential barrier to or facilitator of behavior change.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 102 (actual)
- First submitted
- 13 Oct 2022
- Start date
- 20 Feb 2023
- Primary completion date
- 7 May 2026
- Lead sponsor
- University of Michigan
- Diseases
- Alzheimer disease
- NCT number
- NCT05584241
What you commit to
- Study type: Interventional
- Participants enrolled: 102
- From 20 Feb 2023 to the primary completion date, 7 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Significant neurologic diagnosis (e.g., Alzheimer's dementia or other neurodegenerative dementia, Parkinson's disease, seizure disorder, tumor, multiple sclerosis)
- Neurologic injury (e.g., significant stroke or moderate-severe head injury, defined by loss of consciousness \> 5 minutes, presence of significant post-traumatic amnesia, or the need for extended hospitalization or intervention)
- Severe mental illness (e.g., bipolar disorder, psychosis), moderate-severe mood or anxiety disorder, active substance use disorder (o reduce the likelihood of severe psychological distress, participants must screen negative for moderate-severe depressive or anxiety symptoms at study enrollment.)
Other
- Motor abnormalities indicative of a non-AD etiology
- Inability to provide independent informed consent.
Who the study is looking for
- Diagnosed with Amnestic Mild Cognitive Impairment within the past 12 months,
- Available PET Aβ and tau imaging
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Michigan Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.